Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyPhenoxybenzamine
Identification
- Name
- Phenoxybenzamine
- Accession Number
- DB00925 (APRD00651)
- Type
- Small Molecule
- Groups
- Approved
- Description
An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator. [PubChem]
- Structure
Structure for DB00925 (Phenoxybenzamine)
- Synonyms
- Fenossibenzamina
- Fenoxibenzamina
- Phenoxybenzamine
- Phenoxybenzaminum
- POB
- Product Ingredients
Ingredient UNII CAS InChI Key Phenoxybenzamine Hydrochloride X1IEG24OHL 63-92-3 VBCPVIWPDJVHAN-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Dibenzyline Capsule 10 mg/1 Oral Well Spring Pharmaceutical Corporation 1999-10-01 2017-10-31 US 
Dibenzyline Capsule 10 mg/1 Oral Concordia Pharmaceuticals, Inc 1953-01-26 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Phenoxybenzamine Hydrochloride Capsule 10 mg/1 Oral Prasco, Laboratories 2015-08-11 Not applicable US Phenoxybenzamine Hydrochloride Capsule 10 mg/1 Oral West Ward Pharmaceutical 2015-08-10 Not applicable US Phenoxybenzamine Hydrochloride Capsule 10 mg/1 Oral Par Pharmaceutical 2017-01-24 Not applicable US - International/Other Brands
- Dibenzyline
- Categories
- UNII
- 0TTZ664R7Z
- CAS number
- 59-96-1
- Weight
- Average: 303.826
Monoisotopic: 303.138992038 - Chemical Formula
- C18H22ClNO
- InChI Key
- QZVCTJOXCFMACW-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
- IUPAC Name
- benzyl(2-chloroethyl)(1-phenoxypropan-2-yl)amine
- SMILES
- CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
Pharmacology
- Indication
For the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension.
- Structured Indications
- Pharmacodynamics
Phenoxybenzamine is indicated for the control of episodes of hypertension and sweating that occur with a disease called pheochromocytoma. If tachycardia is excessive, it may be necessary to use a beta-blocking agent concomitantly. Phenoxybenzamine is a long-acting, adrenergic, alpha-receptor blocking agent which can produce and maintain "chemical sympathectomy" by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. Phenoxybenzamine works by blocking alpha receptors in certain parts of the body. Alpha receptors are present in the muscle that lines the walls of blood vessels. When the receptors are blocked by Phenoxybenzamine, the muscle relaxes and the blood vessels widen. This widening of the blood vessels results in a lowering of blood pressure.
- Mechanism of action
Phenoxybenzamine produces its therapeutic actions by blocking alpha receptors, leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure.
Target Actions Organism AAlpha-1A adrenergic receptor antagonistHuman AAlpha-2A adrenergic receptor antagonistHuman UAlpha-2C adrenergic receptor antagonistHuman UAlpha-2B adrenergic receptor antagonistHuman UCalmodulin inhibitorHuman UBeta-2 adrenergic receptor Not Available Human UAlpha-1B adrenergic receptor antagonistHuman UAlpha-1D adrenergic receptor antagonistHuman - Absorption
Twenty to 30 percent of orally administered phenoxybenzamine appears to be absorbed in the active form.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
24 hours
- Clearance
- Not Available
- Toxicity
Symptoms of overdose are largely the result of block of the sympathetic nervous system and of the circulating epinephrine. They may include postural hypotension resulting in dizziness or fainting, tachycardia, particularly postural, vomiting; lethargy, and shock.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Phenoxybenzamine. Experimental Acebutolol Phenoxybenzamine may increase the hypotensive activities of Acebutolol. Approved, Investigational Acemetacin The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acetyl sulfisoxazole The metabolism of Phenoxybenzamine can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Aldesleukin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Aldesleukin. Approved Alfuzosin Alfuzosin may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Aliskiren Phenoxybenzamine may increase the hypotensive activities of Aliskiren. Approved, Investigational Alprenolol Alprenolol may increase the hypotensive activities of Phenoxybenzamine. Approved, Withdrawn Ambrisentan Phenoxybenzamine may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amifostine Phenoxybenzamine may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Amiloride. Approved Amiodarone The metabolism of Phenoxybenzamine can be decreased when combined with Amiodarone. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Phenoxybenzamine. Approved Amobarbital Amobarbital may increase the hypotensive activities of Phenoxybenzamine. Approved, Illicit Amphetamine Amphetamine may increase the hypotensive activities of Phenoxybenzamine. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenoxybenzamine. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Amyl Nitrite. Approved Apalutamide The serum concentration of Phenoxybenzamine can be decreased when it is combined with Apalutamide. Approved, Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenoxybenzamine. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Apraclonidine. Approved Aprepitant The serum concentration of Phenoxybenzamine can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Phenoxybenzamine. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenoxybenzamine. Approved, Investigational Atazanavir The metabolism of Phenoxybenzamine can be decreased when combined with Atazanavir. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Phenoxybenzamine. Approved Atomoxetine The metabolism of Phenoxybenzamine can be decreased when combined with Atomoxetine. Approved Avanafil Avanafil may increase the antihypertensive activities of Phenoxybenzamine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Azilsartan medoxomil. Approved, Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Phenoxybenzamine. Experimental Barbital Barbital may increase the hypotensive activities of Phenoxybenzamine. Illicit Barnidipine Phenoxybenzamine may increase the antihypertensive activities of Barnidipine. Approved Benazepril Benazepril may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Phenoxybenzamine. Approved Benmoxin Benmoxin may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Bepridil Phenoxybenzamine may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Phenoxybenzamine. Approved Bietaserpine Bietaserpine may increase the hypotensive activities of Phenoxybenzamine. Experimental Bimatoprost Bimatoprost may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Phenoxybenzamine. Approved Boceprevir The metabolism of Phenoxybenzamine can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Phenoxybenzamine can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Phenoxybenzamine can be decreased when it is combined with Bosentan. Approved, Investigational BQ-123 Phenoxybenzamine may increase the hypotensive activities of BQ-123. Investigational Bretylium Phenoxybenzamine may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Phenoxybenzamine. Approved Brofaromine Brofaromine may increase the hypotensive activities of Phenoxybenzamine. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenoxybenzamine. Approved, Investigational Bumetanide The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenoxybenzamine. Approved, Investigational Bupranolol Phenoxybenzamine may increase the hypotensive activities of Bupranolol. Approved Cadralazine Cadralazine may increase the hypotensive activities of Phenoxybenzamine. Experimental Cafedrine Phenoxybenzamine may increase the hypotensive activities of Cafedrine. Investigational Canagliflozin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin. Approved Candesartan Phenoxybenzamine may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Candesartan cilexetil may increase the hypotensive activities of Phenoxybenzamine. Approved Candoxatril Candoxatril may increase the hypotensive activities of Phenoxybenzamine. Experimental Captopril Phenoxybenzamine may increase the hypotensive activities of Captopril. Approved Carbamazepine The metabolism of Phenoxybenzamine can be increased when combined with Carbamazepine. Approved, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Phenoxybenzamine. Approved, Investigational Caroxazone Caroxazone may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Carteolol Carteolol may increase the hypotensive activities of Phenoxybenzamine. Approved Carvedilol Phenoxybenzamine may increase the hypotensive activities of Carvedilol. Approved, Investigational Celiprolol Phenoxybenzamine may increase the hypotensive activities of Celiprolol. Approved, Investigational Ceritinib The serum concentration of Phenoxybenzamine can be increased when it is combined with Ceritinib. Approved Chlorothiazide Chlorothiazide may increase the hypotensive activities of Phenoxybenzamine. Approved, Vet Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenoxybenzamine. Approved, Investigational, Vet Approved Chlorthalidone Chlorthalidone may increase the hypotensive activities of Phenoxybenzamine. Approved Cicletanine Phenoxybenzamine may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Phenoxybenzamine may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Phenoxybenzamine. Approved, Investigational Clarithromycin The metabolism of Phenoxybenzamine can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Phenoxybenzamine can be decreased when combined with Clemastine. Approved, Investigational Clevidipine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Clevidipine. Approved, Investigational Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Phenoxybenzamine. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Phenoxybenzamine. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Phenoxybenzamine. Approved Cloranolol Phenoxybenzamine may increase the hypotensive activities of Cloranolol. Experimental Clotrimazole The metabolism of Phenoxybenzamine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Phenoxybenzamine. Approved Cobicistat The metabolism of Phenoxybenzamine can be decreased when combined with Cobicistat. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Phenoxybenzamine. Approved, Investigational Crizotinib The metabolism of Phenoxybenzamine can be decreased when combined with Crizotinib. Approved Cryptenamine Cryptenamine may increase the hypotensive activities of Phenoxybenzamine. Approved Cyclopenthiazide Phenoxybenzamine may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclosporine The metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyclothiazide Cyclothiazide may increase the hypotensive activities of Phenoxybenzamine. Approved Dabrafenib The serum concentration of Phenoxybenzamine can be decreased when it is combined with Dabrafenib. Approved, Investigational Dapagliflozin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dapagliflozin. Approved Darunavir The metabolism of Phenoxybenzamine can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Phenoxybenzamine can be increased when it is combined with Dasatinib. Approved, Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Deferasirox The serum concentration of Phenoxybenzamine can be decreased when it is combined with Deferasirox. Approved, Investigational Delapril Phenoxybenzamine may increase the hypotensive activities of Delapril. Experimental Delavirdine The metabolism of Phenoxybenzamine can be decreased when combined with Delavirdine. Approved Deserpidine Phenoxybenzamine may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Phenoxybenzamine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dexmedetomidine. Approved, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Phenoxybenzamine. Approved Diclofenamide The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Diclofenamide. Approved, Investigational Diethylnorspermine Phenoxybenzamine may increase the hypotensive activities of Diethylnorspermine. Investigational Dihydralazine Dihydralazine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Dihydroergotamine The metabolism of Phenoxybenzamine can be decreased when combined with Dihydroergotamine. Approved, Investigational Diltiazem The metabolism of Phenoxybenzamine can be decreased when combined with Diltiazem. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dinutuximab. Approved, Investigational Dipyridamole The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dipyridamole. Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Phenoxybenzamine. Approved Doxazosin Doxazosin may increase the hypotensive activities of Phenoxybenzamine. Approved Doxycycline The metabolism of Phenoxybenzamine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Phenoxybenzamine can be decreased when combined with Dronedarone. Approved Duloxetine Phenoxybenzamine may increase the orthostatic hypotensive activities of Duloxetine. Approved Efonidipine Phenoxybenzamine may increase the hypotensive activities of Efonidipine. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Phenoxybenzamine. Approved, Vet Approved Enalaprilat Phenoxybenzamine may increase the hypotensive activities of Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Phenoxybenzamine. Experimental Enzalutamide The serum concentration of Phenoxybenzamine can be decreased when it is combined with Enzalutamide. Approved Epanolol Phenoxybenzamine may increase the hypotensive activities of Epanolol. Experimental Eplerenone The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Eplerenone. Approved Epoprostenol Phenoxybenzamine may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Eprosartan may increase the hypotensive activities of Phenoxybenzamine. Approved Erythromycin The metabolism of Phenoxybenzamine can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Esmolol The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Esmolol. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Etacrynic acid. Approved, Investigational Felodipine Phenoxybenzamine may increase the hypotensive activities of Felodipine. Approved, Investigational Fenoldopam Fenoldopam may increase the hypotensive activities of Phenoxybenzamine. Approved Ferulic acid Phenoxybenzamine may increase the hypotensive activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Phenoxybenzamine. Approved, Investigational Fluconazole The metabolism of Phenoxybenzamine can be decreased when combined with Fluconazole. Approved, Investigational Fluvoxamine The metabolism of Phenoxybenzamine can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Phenoxybenzamine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Phenoxybenzamine can be increased when it is combined with Fosaprepitant. Approved Fosinopril Fosinopril may increase the hypotensive activities of Phenoxybenzamine. Approved Fosphenytoin The metabolism of Phenoxybenzamine can be increased when combined with Fosphenytoin. Approved, Investigational Furazolidone Furazolidone may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Phenoxybenzamine can be increased when it is combined with Fusidic Acid. Approved, Investigational Guanabenz Guanabenz may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Phenoxybenzamine. Approved Guanazodine Phenoxybenzamine may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Phenoxybenzamine may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Guanoclor Phenoxybenzamine may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Phenoxybenzamine may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Phenoxybenzamine may increase the hypotensive activities of Guanoxan. Experimental Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Phenoxybenzamine. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Phenoxybenzamine. Experimental Hexamethonium Phenoxybenzamine may increase the hypotensive activities of Hexamethonium. Experimental Hexobarbital Hexobarbital may increase the hypotensive activities of Phenoxybenzamine. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Phenoxybenzamine. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Phenoxybenzamine. Approved Hydrochlorothiazide Phenoxybenzamine may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Idelalisib The metabolism of Phenoxybenzamine can be decreased when combined with Idelalisib. Approved Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Phenoxybenzamine. Approved, Investigational Imatinib The metabolism of Phenoxybenzamine can be decreased when combined with Imatinib. Approved Imidapril The risk or severity of adverse effects can be increased when Imidapril is combined with Phenoxybenzamine. Investigational Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Phenoxybenzamine. Approved Indapamide Indapamide may increase the hypotensive activities of Phenoxybenzamine. Approved Indenolol Phenoxybenzamine may increase the hypotensive activities of Indenolol. Withdrawn Indinavir The metabolism of Phenoxybenzamine can be decreased when combined with Indinavir. Approved Indoramin Indoramin may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Iproclozide Iproclozide may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Irbesartan Phenoxybenzamine may increase the hypotensive activities of Irbesartan. Approved, Investigational Isavuconazole The serum concentration of Phenoxybenzamine can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Phenoxybenzamine can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Phenoxybenzamine. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Phenoxybenzamine. Approved, Vet Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isosorbide Mononitrate. Approved Isoxsuprine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isoxsuprine. Approved, Withdrawn Isradipine The metabolism of Phenoxybenzamine can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Phenoxybenzamine can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Phenoxybenzamine can be increased when it is combined with Ivacaftor. Approved Ketanserin Ketanserin may increase the hypotensive activities of Phenoxybenzamine. Investigational Ketoconazole The metabolism of Phenoxybenzamine can be decreased when combined with Ketoconazole. Approved, Investigational Labetalol Labetalol may increase the hypotensive activities of Phenoxybenzamine. Approved Lacidipine Phenoxybenzamine may increase the hypotensive activities of Lacidipine. Approved, Investigational Latanoprost Latanoprost may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Phenoxybenzamine. Approved, Investigational Levodopa Phenoxybenzamine may increase the orthostatic hypotensive activities of Levodopa. Approved Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Phenoxybenzamine. Approved, Investigational Linsidomine Phenoxybenzamine may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Lofexidine Phenoxybenzamine may increase the hypotensive activities of Lofexidine. Approved, Investigational Lopinavir The metabolism of Phenoxybenzamine can be decreased when combined with Lopinavir. Approved Lorpiprazole The serum concentration of Phenoxybenzamine can be increased when it is combined with Lorpiprazole. Approved Losartan Losartan may increase the hypotensive activities of Phenoxybenzamine. Approved Lovastatin The metabolism of Phenoxybenzamine can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Phenoxybenzamine can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Phenoxybenzamine can be increased when combined with Lumacaftor. Approved Macitentan Phenoxybenzamine may increase the hypotensive activities of Macitentan. Approved Manidipine Phenoxybenzamine may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Mannitol. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Methazolamide The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Methazolamide. Approved Methohexital Methohexital may increase the hypotensive activities of Phenoxybenzamine. Approved Methoserpidine Phenoxybenzamine may increase the hypotensive activities of Methoserpidine. Experimental Methyclothiazide The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Methyclothiazide. Approved Methyldopa Phenoxybenzamine may increase the hypotensive activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Phenoxybenzamine. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Phenoxybenzamine. Approved Metipranolol Phenoxybenzamine may increase the hypotensive activities of Metipranolol. Approved Metolazone Metolazone may increase the hypotensive activities of Phenoxybenzamine. Approved Metoprolol Metoprolol may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Metyrosine Phenoxybenzamine may increase the hypotensive activities of Metyrosine. Approved Mibefradil Phenoxybenzamine may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Mifepristone The serum concentration of Phenoxybenzamine can be increased when it is combined with Mifepristone. Approved, Investigational Minaprine Minaprine may increase the hypotensive activities of Phenoxybenzamine. Approved Minoxidil Minoxidil may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Phenoxybenzamine. Investigational Mitotane The serum concentration of Phenoxybenzamine can be decreased when it is combined with Mitotane. Approved Moclobemide Moclobemide may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Phenoxybenzamine. Approved Molsidomine Molsidomine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Phenoxybenzamine. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Muzolimine Phenoxybenzamine may increase the hypotensive activities of Muzolimine. Experimental Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Phenoxybenzamine. Approved, Investigational Nadolol Phenoxybenzamine may increase the hypotensive activities of Nadolol. Approved Naftopidil Phenoxybenzamine may increase the hypotensive activities of Naftopidil. Investigational Nebivolol Phenoxybenzamine may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The metabolism of Phenoxybenzamine can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Phenoxybenzamine can be decreased when combined with Nelfinavir. Approved Nesiritide The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nesiritide. Approved, Investigational Netupitant The serum concentration of Phenoxybenzamine can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Phenoxybenzamine can be increased when combined with Nevirapine. Approved Nialamide Nialamide may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Nicorandil Nicorandil may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nifedipine. Approved Niguldipine Phenoxybenzamine may increase the hypotensive activities of Niguldipine. Experimental Nilotinib The metabolism of Phenoxybenzamine can be decreased when combined with Nilotinib. Approved, Investigational Nilvadipine Phenoxybenzamine may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimodipine Nimodipine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Phenoxybenzamine. Approved Nitrendipine Phenoxybenzamine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenoxybenzamine. Approved Nitroglycerin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Nitrous acid. Approved, Investigational Obinutuzumab Phenoxybenzamine may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Olaparib The metabolism of Phenoxybenzamine can be decreased when combined with Olaparib. Approved Olmesartan Olmesartan may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Omapatrilat Omapatrilat may increase the hypotensive activities of Phenoxybenzamine. Investigational Osimertinib The serum concentration of Phenoxybenzamine can be increased when it is combined with Osimertinib. Approved Oxprenolol Phenoxybenzamine may increase the hypotensive activities of Oxprenolol. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenoxybenzamine. Approved, Vet Approved Palbociclib The serum concentration of Phenoxybenzamine can be increased when it is combined with Palbociclib. Approved, Investigational Papaverine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Papaverine. Approved, Investigational Pargyline Pargyline may increase the hypotensive activities of Phenoxybenzamine. Approved Penbutolol Phenoxybenzamine may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentobarbital The metabolism of Phenoxybenzamine can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pentolinium Phenoxybenzamine may increase the hypotensive activities of Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Perindopril Perindopril may increase the hypotensive activities of Phenoxybenzamine. Approved Phenelzine Phenelzine may increase the hypotensive activities of Phenoxybenzamine. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Phenobarbital The metabolism of Phenoxybenzamine can be increased when combined with Phenobarbital. Approved, Investigational Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Phenoxybenzamine. Approved Phenytoin The metabolism of Phenoxybenzamine can be increased when combined with Phenytoin. Approved, Vet Approved Pinacidil Pinacidil may increase the hypotensive activities of Phenoxybenzamine. Approved Pindolol Phenoxybenzamine may increase the hypotensive activities of Pindolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pipamperone. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Phenoxybenzamine. Approved Pitolisant The serum concentration of Phenoxybenzamine can be decreased when it is combined with Pitolisant. Approved, Investigational Pivhydrazine Pivhydrazine may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Platelet Activating Factor Phenoxybenzamine may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide Phenoxybenzamine may increase the hypotensive activities of Polythiazide. Approved Posaconazole The metabolism of Phenoxybenzamine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pramipexole. Approved, Investigational Prazosin Prazosin may increase the hypotensive activities of Phenoxybenzamine. Approved Primidone The metabolism of Phenoxybenzamine can be increased when combined with Primidone. Approved, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Propofol. Approved, Investigational, Vet Approved Propranolol Propranolol may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Quetiapine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Quetiapine. Approved Quinapril Quinapril may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Phenoxybenzamine. Approved Ramipril Ramipril may increase the hypotensive activities of Phenoxybenzamine. Approved Ranolazine The metabolism of Phenoxybenzamine can be decreased when combined with Ranolazine. Approved, Investigational Rasagiline Rasagiline may increase the hypotensive activities of Phenoxybenzamine. Approved Remifentanil The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Remifentanil. Approved Remikiren Remikiren may increase the hypotensive activities of Phenoxybenzamine. Approved Rescinnamine Phenoxybenzamine may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Rifabutin The metabolism of Phenoxybenzamine can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Phenoxybenzamine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Phenoxybenzamine can be increased when combined with Rifapentine. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Riociguat Phenoxybenzamine may increase the hypotensive activities of Riociguat. Approved Risperidone Phenoxybenzamine may increase the hypotensive activities of Risperidone. Approved, Investigational Rituximab Phenoxybenzamine may increase the hypotensive activities of Rituximab. Approved Ropinirole The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropivacaine. Approved Rotigotine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Rotigotine. Approved Rucaparib The metabolism of Phenoxybenzamine can be decreased when combined with Rucaparib. Approved, Investigational Sacubitril The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sacubitril. Approved Safrazine Safrazine may increase the hypotensive activities of Phenoxybenzamine. Withdrawn Saprisartan Phenoxybenzamine may increase the hypotensive activities of Saprisartan. Experimental Saquinavir The metabolism of Phenoxybenzamine can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Sarilumab. Approved, Investigational Secobarbital Secobarbital may increase the hypotensive activities of Phenoxybenzamine. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational, Vet Approved Selexipag Phenoxybenzamine may increase the hypotensive activities of Selexipag. Approved Sevoflurane The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sevoflurane. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Phenoxybenzamine. Approved, Investigational Siltuximab The serum concentration of Phenoxybenzamine can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Phenoxybenzamine can be increased when it is combined with Simeprevir. Approved Sitaxentan Phenoxybenzamine may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sotalol The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sotalol. Approved Spirapril Phenoxybenzamine may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Spironolactone. Approved St. John's Wort The serum concentration of Phenoxybenzamine can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Phenoxybenzamine can be increased when it is combined with Stiripentol. Approved Streptokinase The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Streptokinase. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sufentanil. Approved, Investigational Sulfisoxazole The metabolism of Phenoxybenzamine can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Tadalafil Tadalafil may increase the antihypertensive activities of Phenoxybenzamine. Approved, Investigational Talinolol Phenoxybenzamine may increase the hypotensive activities of Talinolol. Investigational Tamsulosin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tamsulosin. Approved, Investigational Telaprevir The metabolism of Phenoxybenzamine can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Phenoxybenzamine can be decreased when combined with Telithromycin. Approved Telmisartan Phenoxybenzamine may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril Phenoxybenzamine may increase the hypotensive activities of Temocapril. Experimental, Investigational Terazosin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Terazosin. Approved Terlipressin Phenoxybenzamine may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Phenoxybenzamine may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Thalidomide. Approved, Investigational, Withdrawn Theodrenaline Phenoxybenzamine may increase the hypotensive activities of Theodrenaline. Investigational Thiamylal Thiamylal may increase the hypotensive activities of Phenoxybenzamine. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Phenoxybenzamine. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Thioridazine. Approved, Withdrawn Tibolone Phenoxybenzamine may increase the hypotensive activities of Tibolone. Approved, Investigational Ticlopidine The metabolism of Phenoxybenzamine can be decreased when combined with Ticlopidine. Approved Ticrynafen Phenoxybenzamine may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol Timolol may increase the hypotensive activities of Phenoxybenzamine. Approved Tizanidine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Phenoxybenzamine can be decreased when it is combined with Tocilizumab. Approved Tolazoline Tolazoline may increase the hypotensive activities of Phenoxybenzamine. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tolcapone. Approved, Withdrawn Tolonidine Phenoxybenzamine may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Phenoxybenzamine. Approved Torasemide Torasemide may increase the hypotensive activities of Phenoxybenzamine. Approved Trandolapril Trandolapril may increase the hypotensive activities of Phenoxybenzamine. Approved Tranylcypromine Tranylcypromine may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Phenoxybenzamine. Approved Treprostinil Treprostinil may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Triamterene. Approved Trichlormethiazide Phenoxybenzamine may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Phenoxybenzamine. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Udenafil Udenafil may increase the antihypertensive activities of Phenoxybenzamine. Approved, Investigational Unoprostone Phenoxybenzamine may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Phenoxybenzamine. Investigational Valsartan Valsartan may increase the hypotensive activities of Phenoxybenzamine. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Phenoxybenzamine. Approved Vemurafenib The serum concentration of Phenoxybenzamine can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Phenoxybenzamine can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Phenoxybenzamine can be decreased when combined with Verapamil. Approved Vincamine Phenoxybenzamine may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Phenoxybenzamine may increase the hypotensive activities of Vinpocetine. Investigational Voriconazole The metabolism of Phenoxybenzamine can be decreased when combined with Voriconazole. Approved, Investigational Xipamide Phenoxybenzamine may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Phenoxybenzamine may increase the hypotensive activities of Xylometazoline. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Phenoxybenzamine. Approved, Investigational, Vet Approved Ziprasidone The metabolism of Phenoxybenzamine can be decreased when combined with Ziprasidone. Approved Zofenopril Phenoxybenzamine may increase the hypotensive activities of Zofenopril. Experimental - Food Interactions
- Not Available
References
- General References
- Caine M, Perlberg S, Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978 Dec;50(7):551-4. [PubMed:88984]
- Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
- External Links
- Human Metabolome Database
- HMDB0015061
- KEGG Compound
- C07435
- PubChem Compound
- 4768
- PubChem Substance
- 46507191
- ChemSpider
- 4604
- BindingDB
- 50017679
- ChEBI
- 8077
- ChEMBL
- CHEMBL753
- Therapeutic Targets Database
- DAP000478
- PharmGKB
- PA450919
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Phenoxybenzamine
- ATC Codes
- C04AX02 — Phenoxybenzamine
- MSDS
- Download (73.8 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Cardiopulmonary Bypass / Open-heart Surgery 1 2 Unknown Status Treatment Congenital Heart Disease (CHD) 1 3 Recruiting Treatment Paraganglioma / Pheochromocytomas 1 4 Completed Treatment Pheochromocytomas 1 Not Available Terminated Treatment Cardiopulmonary Bypass / Congenital Heart Surgery 1
Pharmacoeconomics
- Manufacturers
- Wellspring pharmaceutical corp
- Packagers
- Gallipot
- Murfreesboro Pharmaceutical Nursing Supply
- Wellspring Pharmaceutical
- Dosage forms
Form Route Strength Capsule Oral 10 mg/1 - Prices
Unit description Cost Unit Phenoxybenzamine hcl powd 42.35USD g Dibenzyline 10 mg capsule 8.61USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 39 °C PhysProp logP 4.7 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0103 mg/mL ALOGPS logP 4.26 ALOGPS logP 4.64 ChemAxon logS -4.5 ALOGPS pKa (Strongest Basic) 7.97 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 12.47 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 88.92 m3·mol-1 ChemAxon Polarizability 34.09 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9629 Caco-2 permeable + 0.7367 P-glycoprotein substrate Substrate 0.6059 P-glycoprotein inhibitor I Inhibitor 0.6043 P-glycoprotein inhibitor II Inhibitor 0.5871 Renal organic cation transporter Inhibitor 0.7955 CYP450 2C9 substrate Non-substrate 0.6666 CYP450 2D6 substrate Non-substrate 0.6013 CYP450 3A4 substrate Substrate 0.5937 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Non-inhibitor 0.7714 CYP450 2D6 inhibitor Inhibitor 0.8931 CYP450 2C19 inhibitor Inhibitor 0.8994 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6682 Ames test AMES toxic 0.9107 Carcinogenicity Non-carcinogens 0.7565 Biodegradation Not ready biodegradable 0.9973 Rat acute toxicity 2.1163 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.7145 hERG inhibition (predictor II) Inhibitor 0.5874
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylmethylamines
- Direct Parent
- Phenylmethylamines
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Benzylamines / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides
- Substituents
- Benzylamine / Phenoxy compound / Phenol ether / Phenylmethylamine / Alkyl aryl ether / Aralkylamine / Tertiary aliphatic amine / Tertiary amine / Ether / Organopnictogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- aromatic amine (CHEBI:8077)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1A
- Uniprot ID
- P35348
- Uniprot Name
- Alpha-1A adrenergic receptor
- Molecular Weight
- 51486.005 Da
References
- Stam WB, Van der Graaf PH, Saxena PR: Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br J Pharmacol. 1999 Jun;127(3):661-70. [PubMed:10401556]
- Michel MC, Hanft G, Gross G: Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539-46. [PubMed:7911719]
- Yu Y, Koss MC: Functional characterization of alpha-adrenoceptors mediating pupillary dilation in rats. Eur J Pharmacol. 2003 Jun 20;471(2):135-40. [PubMed:12818701]
- Salles J, Gascon S, Badia A: Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover. Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar;353(4):408-16. [PubMed:8935707]
- Suzuki E, Tsujimoto G, Tamura K, Hashimoto K: Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role. Mol Pharmacol. 1990 Nov;38(5):725-36. [PubMed:1978244]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein homodimerization activity
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
- Gene Name
- ADRA2C
- Uniprot ID
- P18825
- Uniprot Name
- Alpha-2C adrenergic receptor
- Molecular Weight
- 49521.585 Da
References
- Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Epinephrine binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
- Gene Name
- ADRA2B
- Uniprot ID
- P18089
- Uniprot Name
- Alpha-2B adrenergic receptor
- Molecular Weight
- 49565.8 Da
References
- Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Titin binding
- Specific Function
- Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
- Gene Name
- CALM1
- Uniprot ID
- P0DP23
- Uniprot Name
- Calmodulin
- Molecular Weight
- 16837.47 Da
References
- Cimino M, Weiss B: Characteristics of the binding of phenoxybenzamine to calmodulin. Biochem Pharmacol. 1988 Jul 15;37(14):2739-45. [PubMed:3134891]
- Suko J, Wyskovsky W, Pidlich J, Hauptner R, Plank B, Hellmann G: Calcium release from calmodulin and its C-terminal or N-terminal halves in the presence of the calmodulin antagonists phenoxybenzamine and melittin measured by stopped-flow fluorescence with Quin 2 and intrinsic tyrosine. Inhibition of calmodulin-dependent protein kinase of cardiac sarcoplasmic reticulum. Eur J Biochem. 1986 Sep 15;159(3):425-34. [PubMed:3758070]
- Lukas TJ, Marshak DR, Watterson DM: Drug-protein interactions: isolation and characterization of covalent adducts of phenoxybenzamine and calmodulin. Biochemistry. 1985 Jan 1;24(1):151-7. [PubMed:3994963]
- Earl CQ, Prozialeck WC, Weiss B: Interaction of alpha adrenergic antagonists with calmodulin. Life Sci. 1984 Jul 30;35(5):525-34. [PubMed:6146911]
- Kuromi H, Yoshihara M, Kidokoro Y: An inhibitory role of calcineurin in endocytosis of synaptic vesicles at nerve terminals of Drosophila larvae. Neurosci Res. 1997 Feb;27(2):101-13. [PubMed:9100252]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
- Gene Name
- ADRB2
- Uniprot ID
- P07550
- Uniprot Name
- Beta-2 adrenergic receptor
- Molecular Weight
- 46458.32 Da
References
- Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Minneman KP, Theroux TL, Hollinger S, Han C, Esbenshade TA: Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. [PubMed:7969082]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Alpha1-adrenergic receptor activity
- Specific Function
- This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
- Gene Name
- ADRA1D
- Uniprot ID
- P25100
- Uniprot Name
- Alpha-1D adrenergic receptor
- Molecular Weight
- 60462.205 Da
References
- Minneman KP, Theroux TL, Hollinger S, Han C, Esbenshade TA: Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. [PubMed:7969082]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Toxin transporter activity
- Specific Function
- Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
- Gene Name
- SLC22A3
- Uniprot ID
- O75751
- Uniprot Name
- Solute carrier family 22 member 3
- Molecular Weight
- 61279.485 Da
References
- Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
Drug created on June 13, 2005 07:24 / Updated on May 02, 2018 01:18